Skip to main content

Advertisement

SpringerLink
Log in

Oral semaglutide significantly reduces low-density lipoprotein cholesterol level

  • Letter to the Editor
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The data that support the findings of this study are not publicly available due to the confidentiality of the participants; for example, they contain information that could compromise the privacy of research participants, but are available from the corresponding author upon reasonable request.

Abbreviations

AST:

Aspartate aminotransferase

ALT:

Aspartate aminotransferase

γ-GTP:

γ-Glutamyl transpeptidase

eGFR:

Estimated glomerular filtration rate

UACR:

Urinary albumin/creatinine ratio

References

  1. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pederson SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC, PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51.

    Article  CAS  PubMed  Google Scholar 

  2. Dahl K, Brooks A, Almazedi F, Hoff ST, Boschini C, Baekdal TA. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23(7):1594–603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

No funding received.

Author information

Authors and Affiliations

  1. Hidaka Hospital, 886 Nakao-Machi, Takasaki, Gunma, 370-0001, Japan

    Shuichi Okada, Koji Kikkawa, Tetsuro Andou & Kihachi Ohshima

  2. Department of Orthopedic Surgery, Tone Chuo Hospital, 910-1 Numasu-Chou, Numata, Gunma, 378-0012, Japan

    Kazuya Okada

  3. Department of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, 1301 Morris Park Ave., Price 369, Bronx, NY, 10461, USA

    Junichi Okada

  4. Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan

    Eijiro Yamada & Tsugumichi Saito

Authors
  1. Shuichi Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuya Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junichi Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koji Kikkawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eijiro Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tsugumichi Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tetsuro Andou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kihachi Ohshima
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Shuichi Okada and Kihachi Ohshim acared for the patient. Shuichi Okada, Kazuya Okada, Koji Kikkawa, Junichi Okada, Eijiro Yamada, Tsugumichi Saito, Tetsuro Andou, and Kihachi Ohshima attended the clinical conferences on this patient and made important suggestions for the differential diagnosis and therapeutic strategy. Shuichi Okada, and Junichi Okada prepared the manuscript.

Corresponding author

Correspondence to Shuichi Okada.

Ethics declarations

Statement of ethics

The study protocol was reviewed and approved by the review board of Hidaka Hospital (approved reference: 336) on 17 July 2021. The research complies with the guidelines for human studies in accordance with the World Medical Association Declaration of Helsinki. Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Conflict of interest

None of the authors have any potential conflicts of interest associated with this case presentation.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okada, S., Okada, K., Okada, J. et al. Oral semaglutide significantly reduces low-density lipoprotein cholesterol level. Int J Diabetes Dev Ctries (2023). https://doi.org/10.1007/s13410-023-01259-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13410-023-01259-4

Search

Navigation